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Masakazu Yamagishic and Mitsuhiro Kawanoa
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Kanazawa, Japan; bDepartment of General Medicine, Kanazawa University Hospital, Kanazawa, Japan; cDivision of Cardiology, Department of
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ABSTRACT
Objectives: The purpose of our study was to define the clinical characteristics of anti-centromere anti-
body and anti-SS-A/Ro antibody (ACA/SS-A) double positive Sj€ogren’s syndrome (SS) and to clarify the
clinical impact of these antibodies.
Methods: We examined 108 patients (6 males, mean age 57.9 years) with SS who underwent labial
salivary gland biopsy. The patients were divided into four groups by ACA and anti-SS-A/Ro antibody
positivity. Symptoms, laboratory and pathological data, and scleroderma-related data were compared
among the groups.
Results: The cohort consisted of 16 ACA/SS-A double positive, 20 ACA single positive, 67 SS-A single
positive, and 5 ACA/SS-A double negative SS. ACA/SS-A double positive SS were significantly older
than SS-A single positive SS (mean age 71.1 vs. 53.1 years). They had higher EULAR Sj€ogren’s syndrome
disease activity index (ESSDAI) at diagnosis (mean 3.81 vs. 0.50) and higher serum IgG (mean 2009 vs.
1389mg/dL) than ACA single positive SS. No patients developed skin sclerosis during a mean follow-
up period of 45.6 months (range: 1–178).
Conclusion: These results demonstrate that ACA/SS-A double positive SS is distinct from ACA single
positive and SSA single positive SS. The combination of ACA and anti-SS-A/Ro antibody in SS should
deserve greater attention in clinical practice.
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Sj€ogren’s syndrome (SS) is an autoimmune disease charac-
terized by lymphocyte infiltration in the salivary and lacri-
mal glands and production of autoantibodies. Anti-SS-A/Ro
and anti-SS-B/La antibodies are diagnostic markers that are
included in all classification criteria [1–3]. Anti-SS-A/Ro
antibody is positive in 3 3–74% of SS, and anti-SS-B/La anti-
body in 23–52%, meaning on the other hand that some
patients with SS are negative for these antibodies [4].
There are some antibodies other than anti-SS-A/Ro and
anti-SS-B/La antibody in SS, one of which is anti-centromere
antibody (ACA) [5]. Several reports have identified different
clinical characteristics in ACA-positive primary SS as com-
pared with ACA-negative SS, making it a distinct subgroup
of SS [6–17]. ACA-positive SS has intermediate features
between SS and limited scleroderma, with a few such cases
evolving to limited scleroderma [10] and has more severe
sicca symptoms than ACA-negative SS [16]. Anti-SS-A/Ro
antibody positivity in SS is related to hypergammaglobuline-
mia, rheumatoid factor positivity, and antinuclear antibody
positivity, implicating B cell activation [18], although
Katano et al. showed that ACA positivity in SS is not related
to hypergammaglobulinemia [7]. Thus, clinicopathological
features of SS may differ according to the positivity of ACA
or anti-SS-A/Ro antibody.
ACA-positive SS includes two different groups: ACA and
anti SS-A/Ro antibody (ACA/SS-A) double positive SS and
ACA-positive and anti-SS-A/Ro antibody-negative SS (ACA
single positive SS). Considering the role of SS-A and ACA
antibody in SS, these two groups can exhibit different clin-
ical characteristics. However, few data exist regarding the
clinical differences between these two groups or on the clin-
ical characteristics of ACA/SS-A double positive or ACA
single positive SS. The objective of this study was to evaluate
the clinical characteristics of ACA/SS-A double positive SS
and to clarify the clinical impact of ACA and anti-SS-A/Ro
antibody on SS.
Materials and methods
This study was a retrospective cohort study conducted at a
single center in Japan. This study was approved by the
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Ethics Committee of Kanazawa University Hospital.
Informed consent for use of all data was obtained from each
patient, and the research was conducted in compliance with
the Declaration of Helsinki.
Patients
We reviewed 343 patients with labial salivary gland biopsy
from 1998 to 2015 referring to their medical records. We
excluded 151 patients who did not meet the classification cri-
teria of SS, and 53 secondary SS patients with other connect-
ive tissue disease, including 17 with systemic sclerosis (Figure
1). One hundred and thirty nine patients met the Japanese
Ministry of Health revised criteria [1] and/or American
College of Rheumatology criteria [3] with cases with more
than 1 focus score selected for this study. All the patients
were also evaluated using the 2016 American College of
Rheumatology/European League Against Rheumatism classi-
fication criteria [19]. Systemic sclerosis was diagnosed
according to the 1980 American Rheumatology Association
criteria [20] and diffuse or limited scleroderma by LeRoy’s
criteria [21]. Other connective tissue diseases were diagnosed
according to the respective established criteria.
We excluded eight patients who showed low antibody
titers (anti-SS-A/Ro antibody: less than 30 EU, anti-SS-B/La
antibody: less than 25 EU, and ACA: less than 16 EU), and
3 whose antibody profiles had changed during the follow-up
period. Cut-off titer levels for each antibody were defined in
the manufacturer’s protocol. We designed to exclude severe
fibrosis on labial salivary glands suggesting possible overlap
with scleroderma [22], but in practice no patients showed
this feature. Fibrosis in labial salivary gland tissue was eval-
uated according to the criteria of Avouac et al. [22].
Clinical and laboratory assessments
Onset of SS was determined by appearance of Raynaud’s
phenomenon, sicca symptoms, and extraglandular
involvement [13], while disease duration was defined as the
period from onset to presentation to our department.
Follow-up period was defined as the period from first visit
to final visit to our hospital until 2015.
Xerophthalmia, xerostomia, presence or absence of
Raynaud’s phenomenon, the result of Schirmer’s test (5mm
or less defined as positive), ocular staining, and Saxon’s test
(2.0 g or less per 2min defined as positive) were assessed at
the first visit.
Data were classified according to EULAR Sj€ogren’s syn-
drome disease activity index (ESSDAI) [23] and ESSDAI at
diagnosis and the highest ESSDAI during the follow-up was
examined. Each item of 2013 American College of
Rheumatology/European League Against Rheumatism (ACR/
EULAR) systemic sclerosis criteria was evaluated in the
patients with ACA positivity [24]. Dermatologists deter-
mined the presence and severity of any skin sclerosis at
diagnosis, and appearance of skin sclerosis during the fol-
low-up was evaluated from the medical records. We also
looked for pulmonary hypertension, autoimmune hepatitis,
primary biliary cirrhosis, chronic thyroiditis, and malignant
lymphoma. Pulmonary hypertension was defined as a mean
pulmonary arterial pressure more than 25mmHg by right
heart catheterization or pulmonary artery pressure more
than 40mmHg on Doppler echocardiography. Pathological
examinations were necessary to diagnose autoimmune
hepatitis and malignant lymphoma, whereas primary biliary
cholangitis could be diagnosed on the basis of positive
anti-mitochondria antibody and suggestive clinical data.
The diagnosis of chronic thyroiditis was based on positive
anti-thyroglobulin antibody and/or anti-thyroid peroxidase
antibody with hypothyroidism.
Laboratory data and pathological findings of labial saliv-
ary gland biopsy were evaluated. Antinuclear antibody was
detected by immunofluorescent method and rheumatoid fac-
tor by nephelometric assay. We used MESACUP-2test SS-A
(MBL, Nagoya, Japan) for anti-SS-A/Ro antibody,
Figure 1. Flowchart of study population. Japanese classification criteria; Japanese Ministry of Health revised criteria [1], ACR classification criteria; the American
College of Rheumatology classification criteria [3].
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MESACUP-3 test (MBL, Nagoya, Japan) for anti-SS-B/La
antibody, and MESACUP-2 test CENP-B (MBL, Nagoya,
Japan) for ACA measurement. Standard values were defined
by the product manual. All the patients with a low titer of
anti-SS-A/Ro antibody were confirmed to be negative by
Ouchterlony method (Anti-SSA antibody FR, Fujirebio Inc.,
Tokyo, Japan). Serum cytokines were measured with
FlowCytomixTM multiple analyte detection system
(eBioscience, San Diego, CA) according to the man-
ufacturer’s protocol. For the analysis of serum cytokines, we
selected patients who were not receiving steroids or immu-
nosuppressants because these agents might affect the results.
Statistical analysis
Continuous data were expressed as mean ± SD,
Kruskal–Wallis test and Mann–Whitney U test were used
for the analyses. Categorical data were analyzed by chi-
square test and Fisher’s exact test. Differences between
groups were considered significant at p< .05. Unrecorded
data or unperformed tests were regarded as missing data
and these numbers were clarified in the table. Univariate
analysis was performed for three groups other than ACA/
SS-A double negative group that included only five patients.
The Bonferroni procedure was used as a post hoc test. To
assess whether autoantibody profiles affect the severity of
sicca symptoms, multivariate logistic regression analysis was
performed. We used ACA, anti-SS-A/Ro antibody, age at
diagnosis, sex, age at onset, and disease duration as pre-
dictor variables. In multivariate analysis, all data including
the ACA/SSA double negative group were used. Forward
stepwise selection was used for selecting variables for a
regression model. Statistical analysis was performed with
SPSS ver. 21 (IBM Japan, Tokyo, Japan).
Results
Baseline patient profiles
One hundred and eight patients met the inclusion criteria of
this study. Mean age of total participants was 57.9 years and
94.4% were female. Thirty-six patients were positive for
ACA (33.3%), and 83 positive for anti-SS-A/Ro antibody
(76.9%). Sixty-seven patients were SS-A single positive,
twenty ACA single positive, sixteen ACA/SS-A double posi-
tive, and five ACA/SS-A double negative. Using the 2016
American College of Rheumatology/European League
Against Rheumatism classification criteria, 88.9% of the
patients in this study were classified as having primary SS.
ACA/SS-a double positive SS vs. SS-a single positive SS
Clinical characteristics of each group were listed in Table 1.
ACA/SS-A double positive SS showed older age at diagnosis
and at onset than SS-A single positive SS. ACA/SS-A double
positive SS also tended to have lower saliva production as
assessed by Saxon test and lower tear production assessed by
Schirmer’s test and higher focus score in the salivary gland
biopsy than SS-A single positive SS. Serologically ACA/SS-A
double positive SS showed significantly higher antinuclear
antibody (ANA) than SS-A single positive SS (Table 1).
With regard to the disease activity of SS, the data were
similar in these two groups (Table 2). Typical signs such as
lymphadenopathy, salivary gland and lacrimal gland
Table 1. Demographics, clinical, pathological, and laboratory data of the cohort.
ACAþ SSAþ n¼ 16 ACA-SSAþ n¼ 67 ACAþ SSA n¼ 20
Age at diagnosis of SS, mean years ± SD 71.1 ± 11.2 53.1 ± 16.2 61.2 ± 12.3
Female, % 100 92.5 95.0
Disease duration from onset of first symptom, mean years ± SD 9.7 ± 11.8 4.5 ± 7.3 5.8 ± 7.0
Age at onset of SS, mean years ± SD 61.4 ± 15.4 48.7 ± 15.4 55.0 ± 11.8
Follow up period, mean months ± SD 52.1 ± 52.5 40.4 ± 42.6 40.5 ± 50.2
Subjective xerophthalmia, n (%) 9/16 (56.3) 31/67 (46.2) 11/20 (55.5)
Subjective xerostomia, n (%) 14/16 (87.5) 51/67 (76.1) 19/20 (95.0)
Chief complaint of sicca symptoms at diagnosis, n (%) 11/16 (68.8) 25/67 (37.3)‡ 14/20 (70.0)
Schirmer's test (mm), mean ± SD 6.3 ± 3.8 (n¼ 12) 8.7 ± 7.1 (n¼ 44) 5.9 ± 7.2 (n¼ 12)
Positive Schirmer's test, n (%) 8/12 (66.7) 23/44 (52.3) 10/12 (81.9)
Positive ocular staining, n (%) 9/13 (69.2) 24/35 (68.6) 11/14 (78.6)
Saxon's test (g/2min), mean ± SD 0.45 ± 0.51 (n¼ 12) 1.31 ± 1.41 (n¼ 35) 0.67 ± 0.63 (n¼ 14)
Focus score, mean ± SD 4.29 ± 3.74 2.47 ± 2.27 2.70 ± 1.76
Germinal center-like structure, n (%) 4/16 (25.0) 16/67 (23.9) 5/20 (25.0)
aSS-A/Ro(60kDa), n (%) 16/16 (100) 67/67 (100) 0/19 (0)
aSS-B/La, n (%) 5/14 (35.7)† 22/64 (34.4)‡ 0/19 (0)
RF, n (%) 6/13 (46.2) 26/57 (45.6)‡ 1/16 (6.3)
ANA320, n (%) 12/16 (75.0) 25/66 (37.9)‡ 19/20 (95.0)
Both positive RF and ANA320, n (%) 6/13 (46.2) 17/55 (30.9) 1/16 (6.3)
WBC (per mm3), mean± SD 4689 ± 1482 4544 ± 1431‡ 5908 ± 1358
Lymphocytes (per mm3), mean ± SD 1373 ± 448 1489 ± 516‡ 1776 ± 549
Serum IgG (mg/dL), mean ± SD 2009 ± 755† 2281 ± 1234‡ 1389 ± 282
CH50 (U/mL), mean ± SD 47.5 ± 10.0 47.6 ± 11.1 52.8 ± 9.5
C3 (mg/dL), mean± SD 102.9 ± 13.8 99.2 ± 16.8 111.3 ± 21.1
C4 (mg/dL), mean± SD 24.1 ± 8.4 20.4 ± 7.5 24.2 ± 6.3
ACA: anti-centromere antibody; SSA: anti-SSA antibody; SS: Sj€ogren’s syndrome; RF: rheumatoid factor; ANA: anti-nuclear antibody.p< .017 in ACAþ SSAþ vs. ACA-SSAþ.
†p< .017 in ACAþ SSAþ vs. ACAþ SSA.
‡p< .017 in ACA-SSAþ vs ACAþ SSA by Mann–Whitney’s U test or Chi square test.
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swelling, and malignant lymphoma were observed only in
SS-A single positive SS (Table 2).
In systemic sclerosis-related data, ACA/SS-A double posi-
tive SS showed a higher frequency of Raynaud’s phenom-
enon than SS-A single positive SS (Table 3). Pulmonary
involvement was observed more often in ACA/SS-A double
positive SS, and was interstitial pneumonia in all cases. One
patient with ACA/SS-A double positive SS showed pulmon-
ary hypertension and did not meet 2013 ACR/EULAR sys-
temic sclerosis classification criteria, while none of SS-A
single positive SS showed pulmonary hypertension.
ACA/SS-a double positive SS vs ACA single positive SS
Serologically ACA/SS-A double positive SS showed higher
serum IgG than ACA single positive SS. Notably, only 6.3%
of the patients in ACA single positive group met ACR criteria
that required both positive RF and ANA  1:320 (Table 1).
With regard to the disease activity of SS, ACA/SS-A dou-
ble positive SS showed higher ESSDAI at diagnosis and
maximum ESSDAI score during the follow-up than ACA
single positive SS (Table 2). Higher ESSDAI was also noted
in SSA single positive SS. These differences were caused
especially by biological domain and ACA single positive SS
showed no organ involvement requiring steroid or other
immunosuppressive drugs.
Although the frequencies of each domain in 2013 ACR/
EULAR systemic sclerosis criteria were similar between
ACA/SS-A double positive SS and ACA single positive SS,
total score was higher in ACA/SS-A double positive SS
(Table 3). In 36 ACA positive SS, only three patients (8.3%)
met the systemic sclerosis criteria of 2013. No patients
newly developed skin sclerosis and/or Raynaud’s phenom-
enon during a maximum of 178 months and a mean 45.6
months follow-up.
Multivariate analysis
Multivariate logistic regression analysis showed disease dur-
ation and age at onset to be associated with lower salivary
Table 2. ESSDAI score, organ involvement, treatment of the cohort.
ACAþ SSAþ n¼ 16 ACA-SSAþ n¼ 67 ACAþ SSA n¼ 20
ESSDAI at baseline, mean ± SD 3.81 ± 4.68† 4.69 ± 5.27‡ 0.50 ± 0.89
Highest ESSDAI during follow-up, mean ± SD 3.88 ± 4.70† 5.13 ± 5.44‡ 0.65 ± 0.99
Any organ involvements, n (%) 13/16 (81.3)† 56/67 (83.6)‡ 6/20 (30.0)
Increase of ESSDAI score during the follow-up, n (%) 1/16 (6.3) 9/67 (13.4) 2/20 (10.0)
Constitutional, n (%) 2/16 (12.5) 5/67 (7.5) 0/20 (0)
Lymphadenopathy, n (%) 0/16 (0) 4/67 (6.0) 0/20 (0)
Glandular, n (%) 0/16 (0) 3/67 (4.5) 0/20 (0)
Articular, n (%) 0/16 (0) 12/67 (17.9) 1/20 (5.0)
Cutaneous, n (%) 0/16 (0) 3/67 (4.5) 0/20 (0)
Pulmonary, n (%) 4/16 (25.0) 3/67 (4.5) 0/20 (0)
Renal, n (%) 2/16 (12.5) 3/67 (4.5) 0/20 (0)
Muscular, n (%) 0/16 (0) 0/67 (0) 0/20 (0)
Peripheral nervous system, n (%) 0/16 (0) 4/67 (6.0) 0/20 (0)
Central nervous system, n (%) 0/16 (0) 1/67 (1.5) 0/20 (0)
Hematological, n (%) 2/16 (12.5) 20/67 (29.9) 2/20 (10.0)
Biological, n (%) 11/16 (68.8)† 50/67 (74.6)‡ 5/20 (25.0)
Pulmonary hypertension, n (%) 1/16 (6.3) 0/67 (0) 0/20 (0)
Autoimmune hepatitis, n (%) 1/16 (6.3) 2/67 (3.0) 0/20 (0)
Primary biliary cholangitis, n (%) 3/16 (18.8) 2/67 (3.0) 4/20 (20.0)
Chronic thyroiditis, n (%) 2/16 (12.5) 3/67 (4.5) 1/20 (5.0)
Malignant lymphoma, n (%) 0/16 (0) 3/67 (4.5) 0/20 (0)
Treatment
Steroid, n (%) 2/16 (12.5) 10/67 (14.9) 0/20 (0)
Saliva stimulant, n (%) 4/16 (25.0) 20/67 (29.9) 10/20 (50.0)
Ophthalmic drug, n (%) 6/16 (37.5) 18/67 (26.9) 4/20 (20.0)
ESSDAI: EULAR Sj€ogren’s syndrome disease activity index.p< .017 in ACAþ SSAþ vs. ACA-SSAþ.
†p< .017 in ACAþ SSAþ vs. ACAþ SSA.
‡p< .017 in ACA-SSAþ vs. ACAþ SSA by Mann–Whitney’s U test or Chi square test.
Table 3. SSc-related data of the cohort.
ACAþ SSAþ n¼ 16 ACA-SSAþ n¼ 67 ACAþ SSA n¼ 20
Raynaud's phenomenon, n (%) 9/16 (56.3) 8/58 (13.8) 5/20 (25.0)
Puffy fingers, n (%) 1/16 (6.3) ND 3/20 (15.0)
Sclerodactyly, n (%) 0/16 (0) ND 0/20 (0)
Fingertip ulcers, n (%) 0/16 (0) ND 0/20 (0)
Telangiectasia, n (%) 3/16 (18.8) ND 4/20 (20.0)
Abnormal nailfold capillaries, n (%) 7/16 (43.8) ND 6/20 (30.0)
Raynaud's phenomenon and abnormal nailfold capillaries, n (%) 2/16 (12.5) ND 0/20 (0)
Raynaud's phenomenon or abnormal nailfold capillaries, n (%) 11/16 (68.8) ND 8/20 (40.0)
ACR/EULAR SSc criteria score, mean ± SD 6.31 ± 2.21† ND 4.65 ± 2.18
ACR/EULAR SSc criteria score 9, n (%) 2/16 (12.5) ND 1/20 (5.0)
p< .017 in ACAþ SSAþ vs. ACA-SSAþ.
†p< .05 in ACAþ SSAþ vs. ACAþ SSA by Mann–Whitney’s U test or Chi square test.
4 Y. SUZUKI ET AL.
flow rate, defined as 1.0 g or less per 2min for Saxon’s test.
Also, age at diagnosis and absence of anti-SS-A/Ro antibody
were associated with lower lacrimal secretion, defined as
5mm or less per 5min on Schirmer’s test (Table 4). ACA
was not associated with either parameter.
Serum cytokines
To explore factors underlying the differences noted in clin-
ical characteristics, we examined representative Th1, Th2,
and Th17 serum cytokines of 5 ACA/SS-A double positive
SS, 15 SS-A single positive SS, and 9 ACA single positive SS.
Although there was no significant difference, serum levels of
IFN-c, IL-1b, and IL-4 were high in SS-A positive SS. IL-6
was high in SS-A negative SS and IL-17A was high in the
ACA positive group (Table 5). In the comparison of ACA
positive SS and ACA negative SS, ACA positive SS showed
significantly lower levels of IL-1 b (<4.2 pg/ml) [17.2 ± 46.9
vs. 43.5 ± 46.6 (p¼ .035)].
Discussion
This is the first study to focus on the clinical features of
ACA/SS-A double positive SS. Although it was conducted in
a single center, 16 ACA/SS-A double positive SS patients
and 20 ACA single positive SS patients were available for
analysis, representing a relatively large number in compari-
son with previous analyses of ACA positive SS. The results
showed that ACA/SS-A double positive SS was characterized
by high age at diagnosis and onset, and higher ESSDAI than
that of ACA single positive SS.
Higher ESSDAI was observed not only in ACA/SS-A dou-
ble-positive SS but also in SS-A single-positive SS. These
results were attributed to increased organ involvement and
higher scores in the biological domain of the ESSDAI than
those of ACA single positive SS. The presence of anti-SS-A/Ro
antibody in SS is related to activation of humoral immunity
[18], which might explain higher ESSDAI in ACA/SS-A dou-
ble-positive SS and SS-A single-positive SS [25].
ACA has been reported as a sicca-associated antibody,
and in support of this contention Baer et al reported that
ACA-positive SS showed more severe salivary and lacrimal
gland dysfunction than ACA-negative SS [16]. ACA-positive
SS in this study also showed a tendency to lower Saxon’s
test and lower Schirmer’s test scores, while more patients
with ACA complained of sicca symptoms than those without
ACA at presentation, although these differences were not
statistically significant (Table 1). In addition, there were no
differences in subjective dry eye or dry mouth between
ACA/SSA double positive SS and ACA single positive SS.
Therefore, severe sicca symptoms may be characteristic of
ACA-positive SS, with further investigation needed to con-
firm this point.
Differences between ACA-positive SS and scleroderma
should be discussed carefully. We defined scleroderma by
1980 ARA criteria [19] whereas LeRoy relied on limited
scleroderma criteria [20] and excluded skin sclerosis extend-
ing proximal to the metacarpophalangeal joints. Only 3
(8.3%) of 36 ACA-positive SS cases in this study satisfied
ACR/EULAR systemic sclerosis criteria and no case had
sclerodactyly. These results suggest that ACA-positive SS
shows mild symptoms of limited scleroderma consistent
with the findings of Baldini et al. [13]. There have been
numerous reports on sicca symptoms in limited scleroderma
accompanied with labial salivary gland fibrosis [21,26].
Meanwhile, lymphocyte infiltration in labial glands is a char-
acteristic finding of primary SS [21,26]. We excluded
patients with a focus score of 1 or less and severe fibrosis
on lip biopsy. In this regard, we recruited ‘pathologically
diagnosed’ SS. Reliance on these inclusion criteria may lead
to a result that no ACA-positive patient developed skin
sclerosis during the long term follow-up differing from pre-
viously reported ones in which 15 (16.7%) of a total 90
ACA-positive SS patients developed limited scleroderma
[5,6,9,10,15,27]. In this study, only 2 patients (5.6%) had
both Raynaud’s phenomenon and capillary abnormalities.
Furthermore, 22 patients (61.1%) did not have Raynaud’s
phenomenon in ACA-positive SS. Raynaud’s phenomenon
and capillary abnormalities are reported to be predictive of
the development of systemic sclerosis [28], which implies
that few of the ACA positive SS cases in our study will
develop limited scleroderma. Collectively, ACA-positive SS
appears to be a different entity from limited scleroderma.
The frequency of ACA-positive SS in our study was
higher than that noted in previous studies (33.3% vs. 3.7 to
24.6%) [5–16,29]. Although the adoption of different inclu-
sion criteria precludes simple comparisons of the results of
previous studies with ours regarding the frequency of ACA-
positive SS, ACA-positive SS may likely have been underesti-
mated in the past studies.
In this study, we measured serum cytokines in each
group. No significant difference was noted between any of
the three groups probably due to the small number of
patients. However, when divided into two groups,
Table 4. Multivariate logistic regression analysis for factors related to salivary
flow rate and lacrimal secretion.
Predictor valuables OR 95%CI p
Predictor valuables for more than 1.0 g per 2min for Saxon’s test
Age at onset 0.954 0.913–0.996 .034
Disease duration 0.836 0.745–0.939 .002
Predictor valuables for more than 5mm per 5min on Schirmer’s test
Anti-SS-A/Ro antibody 3.981 1.003–15.806 .050
Age at diagnosis 0.966 0.935–0.998 .040







IFN-c (<1.6 pg/ml) 51.4 ± 111.3 67.4 ± 93.2 6.3 ± 10.9
IL-1b (<4.2 pg/ml) 39.4 ± 78.6 43.5 ± 46.6 5.0 ± 2.3
IL-2 (<16.4 pg/ml) 88.1 ± 105.3 71.0 ± 60.2 69.9 ± 72.0
IL-4 (<20.8 pg/ml) 84.6 ± 52.3 86.0 ± 78.7 40.6 ± 24.7
IL-5 (<1.6 pg/ml) 57.4 ± 90.0 31.3 ± 90.4 44.0 ± 64.5
IL-6 (<1.2 pg/ml) 2.1 ± 2.1 3.4 ± 5.0 29.6 ± 85.2
IL-10 (<1.9 pg/ml) 24.0 ± 31.3 16.5 ± 26.3 14.1 ± 28.5
IL-12 p70 (<1.5 pg/ml) 1.5 ± 12.4 1.5 ± 3.2 1.5 ± 0
IL-13 (<4.5 pg/ml) 45.7 ± 71.3 44.4 ± 46.9 55.0 ± 62.5
IL-17A (<2.5 pg/ml) 82.8 ± 110.6 28.4 ± 48.2 103.4 ± 122.0
TNF-a (<3.2 pg/ml) 22.2 ± 42.5 46.6 ± 62.0 33.2 ± 48.2
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ACA-positive SS and ACA-negative SS, the former had
lower serum IL-1b, which is reported to be related to the
fatigue of SS [30]. In this regard, IL-1b may be implicated
in the clinicopathological differences between ACA positive
and negative patients.
The design of this study, namely, a retrospective observa-
tional study conducted in a single center, is a major limita-
tion of this study. In addition, some selection biases were
present because cases were selected from the labial salivary
gland biopsy cohort in our institute. Nevertheless, this is the
first study to describe ACA/SS-A double positive SS includ-
ing ESSDAI, although further prospective study is necessary
to confirm the present results and clinical implications.
Conclusion
In conclusion, we identified several distinct clinical charac-
teristics of ACA/SS-A double positive SS. Affected patients
were older than those with SS-A single positive SS, and had
higher disease activity of SS according to ESSDAI and
higher serum IgG than those with ACA single positive SS.
Anti SS-A antibody positivity was related to the features of
B cell activation such as elevated serum IgG, and ACA posi-
tivity with features of scleroderma such as Raynaud’s phe-
nomenon. Nevertheless, a low frequency of capillary
abnormalities and absence of sclerodactyly in ACA positive
SS were salient characteristics which clearly distinguish the
group from scleroderma. The combination of SS-A and
ACA define the clinical phenotype of SS, and so the com-
bination of these antibodies should attract attention in clin-
ical practice.
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